natgillin/translations-raw huggingface dataset:
Based on a population pharmacokinetic analysis of the PEGASUS study the median ticagrelor Cmax was 391 ng/ml and AUC was 3801 ng*h/ml at steady state for ticagrelor 60 mg.
Na podlagi populacijske farmakokinetične analize v študiji PEGASUS je bila med uporabo 60 mg ticagrelorja mediana Cmax v stanju dinamičnega ravnovesja 391 ng/ml in AUC 3801 ng*h/ml.
Based on a population pharmacokinetic analysis, clearance of bortezomib increased with increasing body surface area (BSA).
Analiza populacijske farmakokinetike je pokazala, da se očistek bortezomiba zveča z zvečanjem telesne površine (BSA – Body Surface Area).
Based on a population pharmacokinetic analysis, gender has no impact on alirocumab pharmacokinetics.
Na podlagi populacijske farmakokinetične analize spol ne vpliva na farmakokinetiko alirokumaba.
Based on a population pharmacokinetic analysis, there are no special instructions for use in the older people.
Za uporabo pri starejših bolnikih glede na analizo farmakokinetike na populaciji ni posebnih navodil.
Based on a population pharmacokinetic analysis, there are no special instructions for use in theolder people.
Za uporabo pri starejših bolnikih glede na analizo farmakokinetike na populaciji ni posebnih navodil.
Based on a population pharmacokinetics (PK) and pharmacokinetic pharmacodynamic (PK/PD) analysis, sunitinib at doses of 25 mg/m2/day on schedule 4/2 in paediatric patients (ages 6-11 and 12-17 years) with GIST is predicted to provide comparable sunitinib plasma exposures, and subsequently safety and efficacy profiles, to those in adult patients with GIST treated at 50 mg/day on schedule 4/2.
Analiza populacijske farmakokinetike (PK) in farmakokinetike/farmakodinamike (PK/PD) kaže, da sunitinib v odmerkih 25 mg/m2/dan po shemi 4/2 pri pediatričnih bolnikih (starih 6-11 in 12-17 let) z GIST predvidoma zagotovi izpostavljenosti sunitinibu v plazmi, ter posledično profil varnosti in učinkovitosti, primerljive s tistimi pri odraslih bolnikih z GIST, ki prejemajo odmerek 50 mg/dan po shemi 4/2.
Based on a population PK analysis in patients with mild (BSA-indexed CrCl 50 to 80 mL/min, n=58) and moderate (BSA-indexed CrCl 30 to 50 mL/min, n=16) renal impairment, mild and moderate impaired renal function had no clinically significant effect on the pharmacokinetics of vismodegib (see section 4.2).
Farmakokinetične analize populacije bolnikov z blago (očistek kreatinina glede na telesno površino 50 do 80 ml/min, n = 58) in zmerno (očistek kreatinina glede na telesno površino 30 do 50 ml/min, n = 16) ledvično okvaro so pokazale, da blago ali zmerno okvarjeno delovanje ledvic ni imelo klinično pomembnega učinka na farmakokinetiko vismodegiba (glejte poglavje 4.2).
Based on a population PK analysis using data from 375 patients, the clearance of elotuzumab increased with increasing body weight supporting a weight-based dose.
Na osnovi analize populacijske farmakokinetike z uporabo podatkov, pridobljenih pri 375 bolnikih, se očistek elotuzumaba povečuje s povečanjem telesne mase, kar podpira odmerjanje na osnovi telesne mase.
Based on a population PK analysis, no dosage adjustments are necessary for patients with mild hepatic impairment (Total Bilirubin [TB] 1.0 x to 1.5 x upper limit of normal [ULN] or aspartate aminotransferase [AST] > ULN).
Po podatkih populacijske farmakokinetične analize odmerkov ni treba prilagajati pri bolnikih z blago okvaro jeter (s koncentracijo celotnega bilirubina v razponu od 1,0 do 1,5-kratnika zgornje meje normalnih vrednosti [ZMN] oziroma s koncentracijo aspartat-aminotransferaze [AST] nad ZMN).
Based on a reduction in body weight in both genders and a delayed preputial separation in males (which may be associated with the reduction in weight), the No-Observed-Effect- Level in juvenile rats was considered to be 6 mg/kg/day.
Na podlagi zmanjšanja telesne mase pri obeh spolih in kasnejšega ločevanja prepucija pri samcih (kar je lahko povezano z zmanjšanjem telesne mase) menijo, da je višina odmerka brez opaznega škodljivega učinka 6 mg/kg/dan.
Based on a study conducted in healthy volunteers, therapeutic doses of retigabine (600-1,200 mg/day) resulted in a minor (8-18%) increase in digoxin AUC following a single oral dose of digoxin.
Študija pri zdravih prostovoljcih je pokazala, da so terapevtski odmerki retigabina (600-1.200 mg/dan) povzročili majhno (8-18%) povečanje AUC digoksina po enem samem peroralnem odmerku digoksina.
Based on a study in obese patients, of the minimal fraction of the dose that was absorbed systemically, two major metabolites, M1 (4-member lactone ring hydrolysed) and M3 (M1 with N-formyl leucine moiety cleaved), accounted for approximately 42 % of the total plasma concentration.
Izsledki študije, v kateri so sodelovali bolniki s preveliko telesno maso, so pokazali, da v majhnem deležu sistemsko absorbirane količine zdravila dva poglavitna presnovka M1 (hidrolizirani 4-členski laktonski obroč) in M3 (M1 z N-formillevcinskim ostankom) zasedata približno 42 % skupne koncentracije v plazmi..
Based on a study in obese patients, of the minimal fraction of the dose that was absorbed systemically, two major metabolites, M1 (4-member lactone ring hydrolysed) and M3 (M1 with N-formyl leucine moiety cleaved), accounted for approximately 42% of the total plasma concentration.
Ugotovitve študije, v kateri so sodelovali bolniki s čezmerno telesno maso, so pokazale, da sta v majhnem deležu sistemsko absorbirane količine zdravila glavna dva presnovka, ki predstavljata približno 42 % skupne koncentracije v plazmi, in sicer M 1 (hidrolizirani 4-členski laktonski obroč) in M3 (M1 s cepljenim N-formillevcinskim ostankom).
Based on a study in obese patients, of the minimal fraction of the dose that was absorbed systemically, two major metabolites, M1 (4-member lactone ring hydrolysed) and M3 (M1 with N-formyl leucine moiety cleaved), accounted for approximately 42% of the total plasma concentration.
Ugotovitve študije, v kateri so sodelovali bolniki s čezmerno telesno maso, so pokazale, da sta v majhnem deležu sistemsko absorbirane količine zdravila glavna dva presnovka, ki predstavljata približno 42 % skupne koncentracije v plazmi, in sicer M1 (hidrolizirani 4-členski laktonski obroč) in M3 (M1 s cepljenim N- formillevcinskim ostankom).
Based on a whole blood mean Cmax concentration of 2.6 μM for temsirolimus in MCL patients receiving the 175 mg dose there is a potential for interactions with concomitantly administered medicinal products that are substrates of CYP3A4/5 in patients treated with the 175 mg dose of temsirolimus (see section 4.5).
Na podlagi povprečne koncentracije Cmax v polni krvi, ki je bila 2,6 μM za temsirolimus pri bolnikih z MCL, ki so prejemali odmerek 175 mg, obstaja možnost interakcij s sočasno uporabljanimi zdravili, ki so substrati za CYP3A4/5 pri bolnikih, zdravljenih s 175-miligramskim odmerkom temsirolimusa (glejte poglavje 4.5).
Based on all field studies, the proportion of mastitis prevented due to herd treatment with Imrestor (Prevented Fraction) is 0.25 (with 95% confidence interval 0.14 – 0.35).
Na podlagi vseh terenskih študij je delež preprečenih primerov zaradi zdravljenja črede z zdravilom Imrestor (delež preprečitve) 0,25 (s 95 % intervalom zaupanja 0,14 - 0,35).
Based on almost 3 years of surveillance following Synflorix introduction, a matched case-control study reported a significant decrease in culture or PCR confirmed IPD due to any vaccine serotype, and IPD due to individual serotypes 6B, 14 and 19A.
Primerjava pred in po NPC kaže značilno zmanjšanje incidence katere koli s kulturo potrjene invazivne pnevmokokne bolezni, invazivne pnevmokokne bolezni zaradi katerega koli serotipa v cepivu in invazivne pnevmokokne bolezni zaradi serotipa 19A.
Based on an analysis of all mCRC clinical trial patients receiving Vectibix monotherapy and in combination with chemotherapy (n = 2,588), the most commonly reported adverse reactions are skin reactions occurring in 93% of patients.
Na podlagi analize vseh bolnikov z mKRR v kliničnih preskušanjih, ki so prejemali monoterapijo z zdravilom Vectibix in zdravilo Vectibix v kombinaciji s kemoterapijo (n = 2.588), so najpogosteje zabeleženi neželeni učinki kožne reakcije; pojavijo se pri 93 % bolnikov.
Based on an analysis of population pharmacokinetics in phase II trials, co-administration of dexamethasone, prochlorperazine, phenytoin, carbamazepine, ondansetron, H2 receptor antagonists, or phenobarbital did not alter the clearance of TMZ.
Na podlagi podatkov analize populacijske farmakokinetike v preskušanjih II. faze sočasno jemanje deksametazona, proklorperazina, fenitoina, karbamazepina, ondansetrona, antagonistov receptorjev H2 ali fenobarbitala ni spremenilo očistka TMZ.
Based on an analysis of population pharmacokinetics in phase II trials, co-administration of dexamethasone, prochlorperazine, phenytoin, carbamazepine, ondansetron, H2 receptor antagonists, or phenobarbital did not alter the clearance of TMZ.
Na podlagi populacijske farmakokinetične analize v preskušanjih faze II sočasna uporaba deksametazona, proklorperazina, fenitoina, karbamazepina, ondansetrona, antagonistov receptorjev H2 ali fenobarbitola ni spremenila očistka TMZ.
Based on an estimated exposure of 566,923 patient treatment years, this results in a reporting rate of approximately 0.20%.
Na osnovi ocenjene izpostavljenosti 566.923 bolnikov-let zdravljenja to pomeni pogostnost poročanja približno 0,20 %.
Based on analysis of population pharmacokinetics and disappearance of ranibizumab from serum for patients with neovascular AMD treated with the 0.5 mg dose, the average vitreous elimination half- life of ranibizumab is approximately 9 days.
Na osnovi analize populacijske farmakokinetike in izločanja ranibizumaba iz seruma pri bolnikih z neovaskularno obliko SDM, zdravljenih z odmerkom 0,5 mg, je povprečen razpolovni čas izločanja ranibizumaba iz steklovine približno 9 dni.
Based on animal data, Eurartesim is suspected to cause serious birth defects when administered during the first trimester of pregnancy (see sections 4.4 and 5.3).
Na podlagi podatkov iz poskusov na živalih se sumi, da povzroča zdravilo Eurartesim hude prirojene okvare, če se daje v prvem trimesečju nosečnosti (glejte poglavji 4.4 in 5.3).
Based on AUC(0 – inf), lenvatinib accounted for 60% and 64% of the total radioactivity in plasma and blood, respectively.
Na podlagi AUC(0–inf) je lenvatinib predstavljal 60 % oziroma 64 % celotne radioaktivnosti v plazmi oziroma krvi.
Based on AUC, the systemic exposure was 0.6 to 1.5 times higher in mice than in humans at the MRHD, whereas based on peak plasma concentrations, the exposure in mice was 5 to 9 times higher.
Sistemska izpostavljenost na podlagi AUC je bila pri miših 0,6 do 1,5-krat večja od sistemske izpostavljenosti pri ljudeh pri največjem priporočenem odmerku za človeka, medtem ko je bila sistemska izpostavljenost na podlagi največje koncentracije v plazmi pri miših 5 do 9-krat večja.
Based on available data from patients receiving cinacalcet in placebo controlled studies and single-arm studies the most commonly reported adverse reactions were nausea and vomiting.
Na osnovi razpoložljivih podatkov o bolnikih, ki so cinakalcet prejemali v študijah, kontroliranih s placebom, in študijah z enim krakom, sta bila najpogosteje poročana neželena učinka navzea in bruhanje.
Based on available data from patients receiving cinacalcet in placebo controlled studies and single-arm studies the most commonly reported adverse reactions were nausea and vomiting.
Na osnovi razpoložljivih podatkov o bolnikih, ki so cinakalcet prejemali v študijah, nadzorovanih s placebom, in študijah z enim krakom, sta bila najpogosteje poročana neželena učinka navzea in bruhanje.
Based on available data, the Committee concluded that PecFent’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Na podlagi razpoložljivih podatkov je zaključil, da so koristi zdravila PecFent večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors ( 4 PI mutations).
Glede na razpoložljive virološke in klinične podatke pri odraslih bolnikih koristi ni pričakovati pri bolnikih s sevi, odpornimi proti več zaviralcem proteaz (≥ 4 mutacije zaviralcev proteaz).
Based on average Cmin concentrations, a predicted average concentration (Cav) could be calculated for 186 subjects dosed with 300 mg.
Na podlagi povprečnih koncentracij Cmin je bilo mogoče za 186 preiskovancev, ki so prejemali 300 mg, izračunati predvideno povprečno koncentracijo (Cav).
Based on best response
Na podlagi najboljšega odziva
Based on CHMP approved protocol, the applicant shall conduct a clinical study with adequate surrogate endpoints on vascular outcomes using imaging techniques to monitor vascular function, disease stabilisation and/or regression.
Na podlagi protokola, ki ga je odobril odbor CHMP, bo predlagatelj izvedel klinično študijo z zadostnimi nadomestnimi opazovanimi dogodki glede žilnih izidov z uporabo tehnik slikanja za spremljanje žilnega delovanja, stabilizacije bolezni in/ali regresije.
based on clinical effect.
na klinični učinek, odmerke
Based on clinical study experience of 361 paediatric patients the majority of which received combination treatment with ZDV or/and ddI, the most frequently reported adverse events related to nevirapine were similar to those observed in adults.
Na podlagi izkušenj iz kliničnih študij, v katera je bilo vključenih 361 otrok,, od katerih je večina prejemala kombinirano zdravljenje z ZDV ali/in ddI, so bili najpogostnejši z nevirapinom povezani neželeni dogodki podobni kot pri odraslih.
Based on clinical trial data, adverse reactions in patients (both adults and children) receiving cholic acid are generally mild to moderate in severity and are provided in the following table.
Glede na podatke iz kliničnih preskušanj je resnost neželenih učinkov pri bolnikih (odraslih in otrocih), ki prejemajo holno kislino, navadno blaga do zmerna, navedeni pa so v spodnji tabeli.
Based on clinical trial experience, Ilaris does not appear to increase the incidence of MAS in SJIA patients, but no definitive conclusion can be made.
Po izkušnjah iz kliničnih študij ne kaže, da bi zdravilo Ilaris povečalo pogostnost sindroma aktivacije makrofagov pri bolnikih s SJIA, vendar dokončnega zaključka ni mogoče podati.
Based on comparable exposure between oral and transdermal rivastigmine (see section 5.2), patients treated with Exelon capsules or oral solution can be switched to Exelon transdermal patches as follows:
Glede na to, da je izpostavljenost rivastigminu primerljiva pri peroralni in transdermalni aplikaciji (glejte poglavje 5.2), lahko bolniki, ki se zdravijo s kapsulami ali peroralno raztopino Exelon, preidejo na zdravljenje s transdermalnimi obliži Exelon na naslednji način:
Based on comparable exposure between oral and transdermal rivastigmine (see section 5.2), patients treated with Prometax capsules or oral solution can be switched to Prometax transdermal patches as follows:
Glede na to, da je izpostavljenost rivastigminu primerljiva pri peroralni in transdermalni aplikaciji (glejte poglavje 5.2), lahko bolniki, ki se zdravijo s kapsulami ali peroralno raztopino Prometax, preidejo na zdravljenje s transdermalnimi obliži Prometax na naslednji način:
Based on comparable exposure between oral and transdermal rivastigmine (see section 5.2), patients treated with rivastigmine capsules or oral solution can be switched to Rivastigmine 3M Health Care Ltd. transdermal patches as follows:
Glede na to, da je izpostavljenost rivastigminu primerljiva pri peroralni in transdermalni aplikaciji (glejte poglavje 5.2), lahko bolniki, ki se zdravijo s kapsulami ali peroralno raztopino rivastigmina, preidejo na zdravljenje s transdermalnimi obliži Rivastigmin 3M Health Care Ltd. na naslednji način:
Based on cross-stud y comparison to 600 mg saquinavir three times daily alone.
Na podlagi medštudijske primerjave s 600 mg samega sakvinavirja trikrat na dan.
Based on cross-study comparison to 1200 mg amprenavir twice daily alone.
Na podlagi medštudijske primerjave s 1200 mg samega amprenavirja dvakrat na dan.
Based on cross-study comparison to 1200 mg amprenavir twice daily alone.
Na podlagi medštudijske primerjave s 400 mg samega atazanavirja enkrat na dan.
Based on cross-study comparison to 400 mg atazanavir once daily alone.
Na podlagi medštudijske primerjave s 1200 mg samega amprenavirja dvakrat na dan.
Based on cumulative reviews a total of 7 cases have been reported demonstrating a likely interaction between orlistat and benzodiazepines.
Na osnovi kumulativnega pregleda je bilo ugotovljeno, da so poročali o 7 primerih, kar dokazuje verjetnost medsebojnega delovanja med orlistatom in benzodiazepini.
Based on cumulative reviews a total of 7 cases have been reported demonstrating a likely interaction between orlistat and benzodiazepines.
Na podlagi zbranih pregledov so poročali skupno o 7 primerih, ki so kazali na verjetno interakcijo med orlistatom in benzodiazepini.
Based on current knowledge, a possible risk for the development of lymphomas, leukaemia or other haematopoietic or solid malignancies in patients treated with a TNF-antagonist cannot be excluded.
Na podlagi trenutnih dognanj pri bolnikih, ki se zdravijo z antagonistom TNF, tveganja za razvoj limfomov, levkemije ali drugih hematopoetičnih ali čvrstih rakavih obolenj ni mogoče izključiti.
Based on data collected from secondary contacts in households where there was an index case with typical pertussis
Na podlagi podatkov zbranih po drugem obisku v gospodinjstvih, v katerih so imeli primer značilnega oslovskega kašlja.
Based on data for other CYP3A inhibitors,
Na osnovi podatkov drugih zaviralcev
Based on data for other CYP3A inhibitors,
Zato je sočasna
Based on data from 1018 patients in eight phase 2 and phase 3 trials, the most commonly reported adverse reactions (> 5%) seen in the first 24 hours after receiving BRINAVESS were dysgeusia (taste disturbance) (16.0%), sneezing (12.5%), and paraesthesia (6.9%).
Na podlagi podatkov o 1.018 bolnikih v osmih preskušanjih 2. in 3. faze so bili najpogosteje poročani neželeni učinki (> 5 %), ki so se pojavili v prvih 24 urah po uporabi zdravila BRINAVESS, disgevzija (motnja okušanja) (16,0 %), kihanje (12,5 %) in parestezije (6,9 %).
Based on data from subjects ranging in age from 5 years to 57 years, there is no apparent effect of age on ataluren plasma exposure.
Podatki, pridobljeni pri osebah, starih od 5 do 57 let, ne kažejo, da bi starost vplivala na izpostavljenost atalurenu v plazmi.
Based on drug exposure, pharmacodynamic response and tolerability, a lower dose of Pegasys is not needed in the geriatric patient (see section 4.2).
Glede na izpostavljenost, farmakodinamični odziv in prenašanje pri starejših bolnikih ni potreben manjši odmerek zdravila Pegasys (glejte poglavje 4.2).
Based on drug interaction studies conducted with the components of Stribild, no clinically significant drug interactions have been either observed or are expected between the components of Stribild and the following drugs: entecavir, famciclovir, famotidine, omeprazole, and ribavirin.
Na podlagi študij medsebojnega delovanja z zdravilom, opravljenih z učinkovinami zdravila Stribild, klinično pomembnih interakcij med učinkovinami zdravila Stribild in naslednjimi zdravili bodisi niso opazili ali jih ni pričakovati: entekavir, famciklovir, famotidin, omeprazol in ribavirin.
Based on drug-drug interaction studies conducted with the components of Odefsey, no clinically significant interactions are expected when Odefsey is combined with the following medicinal products: buprenorphine, naloxone, norbuprenorphine and norgestimate/ethinyl estradiol.
Po podatkih iz študij medsebojnega delovanja, opravljenih z učinkovinami zdravila Odefsey, se ne pričakujejo nobena klinično pomembna medsebojna delovanja, kadar se zdravilo Odefsey uporablja v kombinaciji z naslednjimi zdravili: buprenorfin, nalokson, norbuprenorfin in norgestimat/etinilestradiol.
Based on early data, the combination of YERVOY (ipilimumab) and Zelboraf (vemurafenib, another medicine for the treatment of melanoma) is not recommended due to increased toxicity to the liver.
Na osnovi prvih podatkov kombinacija zdravila YERVOY (ipilimumab) in zdravila Zelboraf (vemurafenib, drugo zdravilo za zdravljenje melanoma) ni priporočljiva zaradi povečanega toksičnega vpliva na jetra.
Based on efficacy and tolerability the dose may be increased step-wise to 50 mg up to 100 mg as necessary.
Glede na učinkovitost in prenašanje se odmerek lahko postopoma zveča na 50 mg do 100 mg, če je to potrebno.
Based on efficacy and tolerability, the dose may be increased step-wise to 50 mg up to 100 mg as necessary.
Glede na učinkovitost in prenašanje je odmerek mogoče postopno povečati na 50 mg in vse do 100 mg, če je potrebno.
Based on efficacy and tolerability, the dose may be increased step-wise to 50 mg up to 100 mg as necessary.
Glede na učinkovitost in prenašanje se odmerek lahko postopoma zveča na 50 mg do 100 mg, če je potrebno.
Based on efficacy and tolerability, the dose may be increased step-wise to 50 mg up to 100 mg as necessary.
Glede na učinkovitost in prenašanje se odmerek lahko postopoma zveča na 50 mg do 100 mg, če je to potrebno.
Based on enoxaparin sodium pharmacokinetics, this difference in steady state is expected and within the therapeutic range.
Glede na farmakokinetiko natrijevega enoksaparinata je ta razlika v stanju dinamičnega ravnovesja pričakovana in je v terapevtskem območju.
Based on epidemiology studies, Gardasil 9 is anticipated to protect against the HPV types that cause approximately: 90% of cervical cancers, more than 95% of adenocarcinoma in situ (AIS), 75-85% of high-grade cervical intraepithelial neoplasia (CIN 2/3), 85-90% of HPV related vulvar cancers,
Na podlagi epidemioloških študij se pričakuje, da cepivo Gardasil 9 varuje pred tipi HPV, ki povzročijo približno: 90 % primerov raka materničnega vratu, več kot 95 % primerov adenokarcinoma in situ (AIS), 75-85 % primerov cervikalne intraepitelijske neoplazije visoke stopnje (CIN 2/3),
Based on estimates from the population pharmacokinetic analysis, East Asian patients had approximately 55% higher plasma eltrombopag AUC(0-) values as compared to patients of other races who were predominantly Caucasian (see section 4.2).
Na osnovi ocen iz analize populacijske farmakokinetike, so bile pri bolnikih vzhodnoazijskega porekla vrednosti AUC(0-) eltrombopaga v plazmi za 55 % večje kot pri bolnikih drugih ras, ki so bili predvsem bele rase (glejte poglavje 4.2).
Based on evidence from animal studies, the major cytochrome P450 isoenzymes are minimally involved in rivastigmine metabolism.
Raziskave na živalih dokazujejo, da pri presnovi rivastigmina le v zelo majhni meri sodelujejo glavni izoencimi s citokromom P450.
Based on experience with oral paliperidone, no dose adjustment is required in patients with mild or moderate hepatic impairment.
Na podlagi izkušenj s peroralnim paliperidonom pri bolnikih z blago ali zmerno jetrno okvaro odmerka ni treba prilagajati.
Based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and is, therefore, not recommended (see section 4.4).
Na podlagi izkušenj z drugimi zdravili, ki vplivajo na sistem renin-angiotenzin, lahko sočasna uporaba diuretikov, ki varčujejo s kalijem, dodatkov kalija, nadomestkov soli, ki vsebujejo kalij, ali drugih zdravil, ki lahko povečajo koncentracijo kalija v serumu (npr. heparin), zviša kalij v serumu in zato ni priporočljiva (glejte poglavje 4.4).